<?xml version="1.0" encoding="UTF-8"?>
<p>The limitations of the study included the retrospective nature, variability of the quantity, quality and sources of the hepatoprotective agents, and the variability, and effectiveness of the antiviral agents. High-quality multi-center, large sample, randomized, double-blind and controlled clinical trials are necessary to confirm the current observations.</p>
